Advertisement

Picture Berlin Partner Hotspot for Startups 650x80px
Organisation › Details

Vaximm (Group)

VAXIMM is a privately held, Swiss/German biotech company that is developing oral T-cell immunotherapies for patients suffering from cancer. VAXIMM’s product platform is based on a live attenuated, safe, orally available bacterial vaccine strain, which is modified to stimulate patients’ cytotoxic T-cells to target specific structures of the tumor. The Company has a pipeline of complementary development candidates targeting different tumor structures. Lead product candidate, oral VXM01, activates killer cells targeting tumor-specific vasculature and certain immune-suppressive cells, thereby increasing immune cell infiltration in solid tumors. VXM01 is currently in clinical development for several tumor types, including brain cancer. VAXIMM also has a neoantigen program (VXM NEO) currently in preclinical development; the Company’s platform allows for fast generation and delivery of personalized T-cell cancer vaccines and may overcome key issues faced by other neoantigen approaches. VAXIMM has a collaboration agreement with China Medical System Holdings (CMS), granting CMS full rights in China and other Asian countries (excluding Japan) to VAXIMM’s existing programs. VAXIMM’s investors include: BB Biotech Ventures, BioMed Partners, CMS, M Ventures and Sunstone Capital. VAXIMM AG is headquartered in Basel, Switzerland. Its wholly owned subsidiary, VAXIMM GmbH, located in Mannheim, Germany, is responsible for the Company’s development activities. *

 

Period Start 2011-01-15 existent
  Predecessor Merck (DE) (Group)
Products Industry therapeutic vaccine
  Industry 2 VXM01 cancer vaccince
     
Region Region Basel BS
  Country Switzerland
  Street 3 Elisabethenstr.
  City 4051 Basel BS
    Address record changed: 2020-12-02
     
Basic data Employees n. a.
     
    * Document for �About Section�: Vaximm AG. (11/12/19). "Press Release: NEC and Vaximm Announce Collaboration to Advance Personalized Neoantigen Cancer Vaccines". Tokyo, Basel & Mannheim.
     
   
Record changed: 2019-11-14

Advertisement

Picture EBD Group Connector Personal Networking in Life Sciences 650x80

More documents for Vaximm (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture [iito] Back into Ad 650x80px




» top